GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reiterated by Beaufort Securities in a research report issued on Friday.

Several other research firms have also recently issued reports on GSK. Jefferies Group restated a “buy” rating and set a GBX 2,000 ($26.11) target price on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. BNP Paribas restated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Friday, July 29th. JPMorgan Chase & Co. restated a “neutral” rating on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Deutsche Bank AG restated a “hold” rating and set a GBX 1,700 ($22.19) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 28th. Finally, Sanford C. Bernstein set a GBX 1,755 ($22.91) target price on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Thursday, July 28th. Three analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of GBX 1,676.44 ($21.88).

GlaxoSmithKline plc (LON:GSK) opened at 1645.50 on Friday. GlaxoSmithKline plc has a 52-week low of GBX 1,227.50 and a 52-week high of GBX 1,716.50. The company’s market capitalization is GBX 79.99 billion. The stock has a 50 day moving average of GBX 1,656.11 and a 200-day moving average of GBX 1,528.28.

The firm also recently announced a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th will be paid a GBX 19 ($0.25) dividend. The ex-dividend date of this dividend is Thursday, August 11th. This represents a yield of 1.12%.

In other GlaxoSmithKline plc news, insider Witty,Sir Andrew P sold 10,000 shares of the stock in a transaction on Wednesday, July 27th. The stock was sold at an average price of GBX 1,693 ($22.10), for a total value of £169,300 ($220,989.43). Also, insider Slaoui,Moncef bought 28 shares of GlaxoSmithKline plc stock in a transaction on Friday, August 12th. The stock was acquired at an average price of GBX 2,208 ($28.82) per share, for a total transaction of £618.24 ($807.00).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.